Summary
In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose.
After the EORTC Clinical Screening Group phase II trial we have conducted an “expected difference method” comparative phase II trial using the combination DOX, VCR, CPM, FU and the combination of MTX (10mg/m2), VCR, CPM and FU on a population of 50 breast carcinoma patients similar to those taking part in the first study.
The reasons for similarity of action will be presented and discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rubens RD: Breast cancer. In HM Pinedo (ed.): The EORTC Cancer Chemotherapy Annual 2. Elsevier, Amsterdam, 1981
Bonandonna G, Valagussa P: Chemotherapy of breast cancer, current views and results. Int J Rad Oncol Biol and Phys 9:279–297, 1983
Gouveia J, Misset J L, Bayssas M, Belpomme D, De Vassal F, Delgado M, Gil M, Hayat M, Jasmin C, Machover D, Musset M, Pico J L, Ribaud P, Schwarzenberg L, Mathe G: Immunotherapy by BCG interspersed with AVCF combination chemotherapy in advanced breast carcinoma (Abstract 49). Med Oncol 4:13, 1978
Powles TJ, Smith IE, Ford HT, Coombes RC, Mary Jones J, Gazet JC: Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet, 1(8168):580–582, 1980
Dantchev D, Paintrand M, Bourut C, Pignot I, Maral R, Mathe G: Cardiac and skin toxicity of mitoxantrone in comparison with anthracylines. In G Mathe, E Mihicen and P Reizenstein (eds.): Current Drugs and Methods of Cancer Treatment. Masson Publ., New York, 1983
Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP: Dihydroxyanthracenedione: A promising new drug in the treatment of metastatic breast cancer. Ann Int Med 95:694–697, 1981
De Jager R, Cappelaere P, Armand JP, Keiling R, Fargeot P, Bastit P, Van Glabbeke M, Renard J, Earl H, Rubens R, Stuart-Harris R, Smith I, Smythe J, Mathe G: An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. Eur J Cancer (in press)
Gehan EA: Update on planning phase II trials, June 1984
Lee YJ, Wesley RA: Statistical contributions to phase II in cancer: interpretation, analysis and design. Seminars Oncol 8:4, 1981
Misset JL, Gaget H, Mathe G: Les essais phase II comparatifs de confirmation de l'hypothese nulle. Leur interet, notamment en oncologie. Biomed Pharmacother 37:58–59, 1983
Miller AB, Hoogstraten B, Staquet M, Winkler: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, Benjamin RS and Haynie TP: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Oncol 2:2, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Metz, R., Delgado, M., Keiling, R. et al. Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. Invest New Drugs 3, 163–166 (1985). https://doi.org/10.1007/BF00174164
Issue Date:
DOI: https://doi.org/10.1007/BF00174164